Yearly STL Archives: 2026

Delgocitinib 2% cream is the first topical pan-JAK inhibitor approved for moderate-to-severe chronic hand dermatitis. This review covers its mechanism, phase 2 and DELTA 1–3 trial results, long-term safety without a boxed warning, and its role as a steroid-sparing option in clinical practice.

Mild hidradenitis suppurativa still has no approved treatments. This review covers emerging topical options for Hurley stage I disease, including ruxolitinib, roflumilast and clascoterone, plus new HS cleansers and a Catalytic Treatment Matrix for faster wound healing after surgical deroofing.

Update on dupilumab (Dupixent®), now FDA-approved for chronic spontaneous urticaria in children 2-11 years, and adapalene 0.1% + benzoyl peroxide 2.5% (Differin® Epiduo® Acne Gel), now OTC. Plus: bemotrizinol, the first new FDA sunscreen filter in 20+ years, and a Health Canada peptide warning.

Most molluscum contagiosum lesions resolve on their own, but symptomatic or cosmetically troubling cases have long been managed with off-label agents and destructive procedures. That changed with the FDA approval of cantharidin 0.7% drug-device applicator in 2023 and berdazimer 10.3% gel in 2024. This review examines the trial evidence behind both, compares them with potassium hydroxide, salicylic acid, cryotherapy, curettage, and pulsed dye laser, and addresses the treatment gaps that remain in immunocompromised patients and those with atopic dermatitis.

The skin has long been read as a mirror of internal disease, but its relationship with bone is less familiar. Dermis and bone share a common embryonic origin, overlapping cell lineages, and collagen as a structural backbone. This review examines the skin-bone axis — vitamin D signalling, cystatin A, inflammatory dermatoses, corticosteroid effects on bone, cutaneous signs of metabolic and autoinflammatory bone disease, and the gut microbiome's role in both — and makes the case for a multidisciplinary approach to healthy aging.

Update on Dupilumab for SC injection (Dupixent®) and Adapalene 0.1% + benzoyl peroxide 2.5% acne treatment (Differin® Epiduo® Acne Gel). Also, in June 2026, bemotrizinol – long used internationally as Tinosorb® S – has become the first new FDA‑approved sunscreen filter in over 20 years.

Exosomes are emerging as a promising biologic platform in dermatology, with growing evidence supporting their role in wound healing, skin regeneration, pigmentation control, and inflammatory skin disorders through immune modulation and tissue repair mechanisms.

Discover how zasocitinib, a next-generation selective TYK2 inhibitor, may redefine psoriasis treatment with targeted efficacy, reduced off-target JAK effects, and promising late-stage clinical results.

Update on Icotrokinra 200 mg tablet (Icotyde™), Difamilast 1% ointment (Adquey™), and Epinephrine nasal spray 2 mg/0.1 mL (Neffy®).

Erratum to the deuruxolitinib for alopecia areata review, including revised safety data, launch information, and clinical comparisons.

A closer look at the science behind one of the oldest skincare ingredients. Dr. Vincent Richer explores how oat oil stimulates ceramide synthesis, oat flour supports a healthy microbiome, and oat extract dampens inflammation—and why Aveeno Healing Ointment® offers a petrolatum-free path to barrier repair.

Review of topical ruxolitinib as a promising JAK inhibitor for mild to moderate hidradenitis suppurativa, including early trial results, safety data, and its role in addressing unmet treatment needs.

Read about current and emerging hyperhidrosis treatments including sofpironium bromide, glycopyrronium wipes, botulinum toxin, targeted alkali thermolysis, microwave therapy, and laser options.

Update on Nemolizumab SC injection (Nemluvio®), Gepotidacin tablets (Blujepa®), and Zoliflodacin for oral suspension (Nuzolvence®).

Deuruxolitinib (FDA-approved July 2024) is an oral JAK1/JAK2 inhibitor for severe alopecia areata. Learn about its mechanism, THRIVE-AA trial results showing rapid hair regrowth, safety profile, and how it compares to baricitinib and ritlecitinib.

Discover icotrokinra, a groundbreaking oral peptide that targets the IL-23 receptor to treat moderate-to-severe plaque psoriasis. Clinical trials show it delivers biologic-like skin clearance in a convenient once-daily pill.

Update on Calcipotriene and betamethasone dipropionate cream, 0.005%/0.064% (Wynzora®), Roflumilast foam 0.3% (Zoryve®), Roflumilast cream 0.05% (Zoryve®), and Lidocaine topical system 10% (Bondlido®)